A Phase 3 interventional study of dutogliptin and placebo in Type 2 Diabetes Mellitus, sponsored by Phenomix. Terminated at 97 sites in 7 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2010-08-11.
Sponsored by Phenomix · Phase 3, Interventional, and Treatment
The purpose of this study is to demonstrate the efficacy of dutogliptin over 26 weeks (as evidenced by placebo-corrected changes in HbA1c relative to baseline), to demonstrate safety and tolerability of dutogliptin, and to demonstrate changes in fasting plasma glucose over 26 weeks.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 700 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Phenomix is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
dutogliptin/PHX1149T
Drug: dutogliptin
Plabeco
Drug: placebo
400 mg
Also known as: PHX1149T
Primary objective is to demonstrate the efficacy of dutogliptin, as evidenced by placebo-corrected changes in HbA1c relative to baseline.
Time frame: 26 weeks
Demonstrate safety and tolerability of dutogliptin
Time frame: 26 weeks
• Demonstrate changes in fasting plasma glucose
Time frame: 26 weeks
This study is terminated, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Phenomix